

44. 1. #7

Form 1449 US Department of Commerce Patent and Trademark Office DEC 05 2001 PATENT & TRADEMARK OFFICE	ATTY DOCKET NO: P-LJ 4859	SERIAL NO. 09/922,227
	APPLICANT: Ruoslahti and Pasqualini	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 2, 2001	GROUP: 1619

1632

RECEIVED
FEB 19 2002
CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
5/7/02	4,399,124	08.16.83	Fauve	424	177	
	4,897,464	01.30.90	Vallee et al.	530	350	6.25.87
	5,081,034	01.14.92	Bevilasqua et al.	435	252.33	11.14.88
	5,098,833	03.24.92	Lasky et al.	435	69.1	2.23.89
	5,216,131	06.01.93	Lasky et al.	530	350	10.31.91
	5,225,538	07.06.93	Capon et al.	530	387.3	12.16.91
	5,270,163	12.14.93	Gold et al.	435	6	8.17.92
	5,288,846	02.22.94	Quertermous et al.	435	172.3	8.3.92
	5,304,640	04.19.94	Lasky et al.	536	23.5	2.13.92
	5,415,874	05.16.95	Bender et al.	424	520	10.31.89
	5,428,130	06.27.95	Capon et al.	530	350	12.8.92
	5,453,362	09.26.95	Lamarco et al.	435	69.1	4.12.93
	5,506,126	04.09.96	Seed et al.	435	172.3	10.18.93
	5,660,827	08.26.97	Thorpe et al.	424	152.1	6.1.95
	5,622,699	04.22.97	Ruoslahti et al.	424	93.6	09.11.95
	5,688,935	11.18.97	Stephens et al.	536	23.1	5.3.95
	6,068,829	05.30.00	Ruoslahti et al.	424	9.1	6.23.97

EXAMINER <i>Sarah D. Pate</i>	DATE CONSIDERED <i>4/31/02</i>
----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office OIPE DEC 05 2001	ATTY DOCKET NO: P-LJ 4859	SERIAL 09/922 227
	APPLICANT: Ruoslahti and Pasqualini	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 2, 2001	GROUP: 1619

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
SDP	CA2,101,942	01.30.01	CANADA	C07K	1/13	
	WO96/34875	07.11.96	WIPO	C07H	21/012	
	WO96/34874	07.11.96	WIPO	C07H	21/02	
	0 135 277	07.11.84	Europe EPO	C07K	7/02	
	0 639 584	22.2.95	Europe EPO	C07K	1/04	
	WO95/14714	01/06/95	WIPO	C07K/14	75	
	WO92/00091	09.01.92	WIPO	A61K/37	02	
	WO92/03461	05.03.92	WIPO	C07H/17	00	
	WO92/06191	16.04.92	WIPO	C12N/15	10	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

SDP	Baillie et al., "Tumour Vasculature-A Potential Therapeutic Target" <u>British J. Cancer</u> 72:257-267 (1995)
	Beinfeld, M., "The Distribution and Chromatographic Characterization of An Amino-Terminal Fragment of Cholecystokinin (CCK) 58 In Rat Brain," <u>Biochem. Biophys. Res. Comm.</u> 127:720-725 (1985)
	Burioni et al., "Recombinant Human Fab to Glycoprotein D Neutralizes Infectivity and Prevents Cell-to-Cell Transmission of Herpes Simplex Viruses 1 and 2 In Vitro" <u>Proc. Natl. Acad. Sci. USA</u> 91:355-359 (1994)
	Burrows and Thorpe, "Vascular Targeting-A New Approach to the Therapy of Solid Tumors" <u>Pharmac. Ther.</u> 64:155-174 (1994)
	Burton et al., "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus From Combinatorial Libraries of Asymptomatic Seropositive Individuals" <u>Proc. Natl. Acad. Sci. USA</u> 88:10134-10137 (1991)
	Cattani et al., "Cloning and Characterization of Human Recombinant Antibody Fab Fragments Specific for Types 1 and 2 Herpes Simplex Virus" <u>Chem. Abstr. Immunochimistry</u> 123:141201m (1995)

EXAMINER <i>Scott D. Pritch</i>	DATE CONSIDERED 10/31/02
------------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 DEC 05 2001 RECEIVED OFFICE 600/2900	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4859	SERIAL NO. 09/9221227
		APPLICANT: Ruoslahti and Pasqualini	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: August 2, 2001	GROUP: 1619

1632

SDP		Cattani et al., "Cloning and Characterization of Human Recombinant Antibody Fab Fragments Specific for Types 1 and 2 <i>Herpes Simplex Virus</i> " <u>Microbiologica</u> 18:135-142 (1995)
		Davis et al., "Use of a High Affinity DNA Ligand in Flow Cytometry" <u>Nucl. Acids Res.</u> 24:702-706 (1996)
		Drolet et al., "An Enzyme-linked Oligonucleotide Assay" <u>Nat. Biotech.</u> 14:1021-1025 (1996)
		Dvorak et al., "Structure of Solid Tumors and Their Vasculature: Implications for Therapy with Monoclonal Antibodies" <u>Cancer Cells</u> 3:77-85 (1991)
		Goetz et al., "Lu-ECAM-1-Mediated Adhesion of Melanoma Cells to Endothelium Under Conditions of Flow" <u>Int. J. Cancer</u> 65:192-199 (1996)
		Gold et al., "Diversity of Oligonucleotide Functions" <u>Annu. Rev. Biochem.</u> 64:763-797 (1995)
		Goodson et al., "High-affinity Urokinase Receptor Antagonists Identified with Bacteriophage Peptide Display" <u>Proc. Natl. Acad. Sci. USA.</u> 91:7129-7133 (1994)
		Green et al., "Comprehensive Chemical Modification Interference and Nucleotide Substitution Analysis of an RNA Pseudoknot Inhibitor to HIV-1 Reverse Transcriptase," <u>J. Mol. Biol.</u> 247:60-68 (1995)
		Hart et al., "Cell binding and internalization by filamentous phage display peptide libraries" <u>Nature</u> 380:364-366 (1996)
		Hendrikx et al., "Homing of Fluorescently labeled murine hematopoietic stem cells," <u>Experimental Hematology</u> 24:129-140 (1996)
		Hicke et al., "DNA Aptamers Block L-Selectin Function <i>In Vivo</i> " <u>J. Clin. Invest.</u> 98:2688-2692 (1996)
✓		Huang et al., "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature" <u>Science</u> 275:547-550 (1997)

EXAMINER <i>Scott D. Prike</i>	DATE CONSIDERED 10/31/02
-----------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office DEC 05 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO: P-LJ 4859	SERIAL NO. 09/922227
	APPLICANT: Ruoslahti and Pasqualini	
	FILING DATE: August 2, 2001	GROUP: 1619

SDP		Koivunen et al., "Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins," <u>Bio. Technology</u> 13:265-270 (1995)
		Koivunen et al., "Selection of Peptides Binding to the $\alpha_5\beta_1$ Integrin from Phage Display Library," <u>J. Biol. Chem.</u> 268:20205-20210 (1993)
		Lappi, Douglas A., "Tumor Targeting Through Fibroblast Growth Factor Receptors" <u>Cancer Biology</u> 6:279-288 (1995)
		Leff, D., "NeXstar Previews 'PASS' for Downstream Synthesis of Therapeutic Oligos" <u>Bioworld Today</u> 8:2&4 (1997)
		Martiny-Baron and Marmé, "VEGF-mediated Tumour Angiogenesis: A New Target for Cancer Therapy" <u>Current Biology</u> 6:675-680 (1995)
		Miner et al., "Clonal Drift of Cell Surface, Melanogenic, and Experimental Metastatic Properties of in vivo-selected, Brain Meninges-colonizing Murine B16 Melanoma" <u>Cancer Research</u> 42:4631-4638 (1982)
		Mitjans et al., "An anti- α_v -integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," <u>J. Cell Sci.</u> 108:2925-2838 (1995)
		Nakano et al., "Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes," <u>Eur. J. Immunol.</u> 27:215-221 (1997)
		Pasqualini et al., " α_v Integrins as receptors for tumor targeting by circulating ligands," <u>Nature Biotech.</u> 15:542-546 (1997)
		Pasqualini and Ruoslahti, "Organ Targeting in vivo Using Phage Display Peptide Libraries" <u>Nature</u> 380:364-366 (1996)
		Pauli et al., "Organ-preference of Metastasis," <u>Cancer and Metastasis Reviews</u> 9:175-189 (1990).
		Smith and Smith, "Identification of New Protein Kinase-Related Genes in Three Herpesviruses, Herpes Simplex Virus, Varicella-Zoster Virus, and Epstein-Barr Virus," <u>J. Virology</u> 63:450-455 (1989)

EXAMINER <i>Scott D. Priole</i>	DATE CONSIDERED 10/31/02
------------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 DEC 05 2001 U.S. PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4859	SERIAL NO. 09/922,227
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Ruoslahti and Pasqualini FILING DATE: August 2, 2001 GROUP: 1619 1632	

SDP		Tatemoto et al., "Isolation of a brain peptide identical to the intestinal PHI (peptide HI)," <u>FEBS Letters</u> 153:248-253 (1983)
↓		Zhu et al., "Mediation of Lung Metastasis of Murine Melanomas by a Lung- specific Endothelial cell Adhesion Molecule" <u>Proc. Natl. Acad.</u> 88:9568- 9572 (1991)

EXAMINER <i>Scott D Priole</i>	DATE CONSIDERED 10/31/02
-----------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.